サラブレッド馬における静脈麻酔薬アルファキサロンの臨床薬物特性に関する研究

全文

(1)Title. サラブレッド馬における静脈麻酔薬アルファキサロンの臨床薬物特性に関する研究( 本文(Fulltext) ). Author(s). 和久野, 愛. Report No.(Doctoral Degree). 博士(獣医学) 乙第168号. Issue Date. 2020-03-13. Type. 博士論文. Version. ETD. URL. http://hdl.handle.net/20.500.12099/79379. ※この資料の著作権は、各資料の著者・学協会・出版社等に帰属します。.

(2) . 9/<),×

(3) . Ô³ÙÆµ;.. => ´lµr

(4) Ï £. 2019 k. gÐ]`]`ÒÄUQ` £¡ XDÊ s.

(5)

(6) . 9/<),×

(7) . Ô³ÙÆµ;.. => ´lµr

(8) Ï £ . XDÊ s.

(9)

(10) À Á . AUC0-inf area under the blood concentration-time curveÚÑÎ ¶C mÎ°AÕ¢Û AUC0-tlast; area under the blood concentration-time curveÚªaËÎ ¶ CmÎ°AÕ¢Û AUMC0-inf; area under the first movement curveÚÑÎ 1 7@6>+ °AÕ¢Û AUMC0-tlast; area under the first movement curveÚªaËÎ 1 7@6 >+°AÕ¢Û Cl; clearanceÚ®:9>#Û CRI; constant rate infusionÚyÔ³LuBÛ DAP; diastolic arterial pressureÚwnO³[Û ETSEVO; end tidal sevoflurane concentrationÚªW$2.;9>mÛ GABAA; gamma aminobutyric acid AÚ>34-ÇÈ AÛ HR; heart rateÚqv{Û IPPV; intermittent positive pressure ventilationÚÎÓ[zÛ JRAßJapan Racing AssociationÚ~ C^¥×FÛ LCP; locking compression plateÚ=)>>0<)!8>0<@+Û MAP; mean arterial pressureÚj\O³[Û PaCO2; arterial partial pressure of CO2ÚO³¶EÈP©M[Û PaO2; arterial partial pressure of O2ÚO³¶È©M[Û PIVA; partial intravenous anesthesiaÚÅMÔ³ÙÆÛ RR; respiratory rateÚWV{Û.

(11) SAP; systolic arterial pressureÚT±O³[Û t1/2; elimination half lifeÚ_RÛ TIVA; total intravenous anesthesiaÚKÔ³ÙÆÛ Vdss; volume ofdistribution atsteady stateÚaitMhc¢Û . .

(12) .

(13) . ¯ Â. ?????????? 1. ¦ 1 ¤Þ6*+4">Ý4'%95ÌÔA ;.. =>Ü&4>. (1>&@; eJ?ºÉ ´lr

(14) WVp¨

(15) SoÖ Ã 1. ¯ ¼. ?????????? 6. 2. |} 1ÛH¿×. ?????????? 8. 2ÛÙÆbØ0=+@;. ?????????? 9. 3ÛeJºÉ ¾I. ?????????? 10. 4Û¬½». ?????????? 11. 3. « . ?????????? 11. 4. ² d. ?????????? 12. 5. f x. ?????????? 16. 6. Y ¹. ?????????? 17. ¦ 2 ¤Þ6*+4">Ý4'%95ÌÔA 2 Ë

(16) ;. => µOt`µN`r ¾I 1. ¯ ¼. ?????????? 23. 2. |} 1ÛH¿×. ?????????? 25.

(17) 2ÛÙÆbØ0=+@;. ?????????? 25. 3ÛeJºÉ ¾I. ?????????? 26. 4Û¶C;.. ?????????? 27. 5Û;.. =>M. => µOt». 6Û¬½». ?????????? 28 ?????????? 28. 3. « . ?????????? 29. 4. ² d. ?????????? 30. 5. f x. ?????????? 34. 6. Y ¹. ?????????? 35. ¦ 3 ¤ÞÍÎ

(18) SLZa¸

(19) $2.;9>VJÙÆ

(20) ;.. =>Ý. 6*+4">yÔ³LuBGÙÆ

(21) ÙÆ§· 1 7 1. ¯ ¼. ?????????? 42. 2. |} 1Û7×. ?????????? 44. 2ÛÙÆO. ?????????? 44. 3ÛW¡n¸. ?????????? 46. 3. «²d. ?????????? 46. 4. f x. ?????????? 49. 5. Y ¹. ?????????? 50. ® x. ?????????? 53.

(22) `x. ?????????? 57. Ã Ç. ?????????? 69.

(23) ¯ Â. 1.

(24) +)0#:@+ d. 9/<),¥Ä×Ü~×Übm +<@. %>ÁÜ´4

(25) ©£

(26) Ñt

(27) ³ ÜÌO Oi X¥X Þ82ß

(28) ÜKÆ ÙÆA W¡n¸Ïr

(29) XC Ü{¥Äg^ wcW¡n¸ÚÛs=¸LZa¸Ûn¸{K4 ª 70ÝFÜ /

(30) Ü0&."@3># tM*Í cmn¸ÜvL Ñ¹n¸Ür tMGDn¸ Ü n¸LcXg

(31). . Þ82ß

(32) n¸o¸ J*

(33) 1 n¸LcX P Ü Ék ~ C^¥×FÚJRAÛzÀL

(34) ®n¸0{kVB;J

(35) I

(36) Ün¸Lc

(37) hÜm ÙÆ§o¸¾

(38)

(39) × ÙÆÏÄ.u ª 1ÝTK

(40) Þ80ßÜ {Z ª 0.1ÝÞ15ßÃ

(41) ÜC Ü. 9/<),4Ð 500. kg @e]R

(42) BÜr »Y Ü9× Å¦

(43) ½ÔÛq ºL .uÜÙÆµ WVp p?5

(44) «² È©HË3AÜ4&(@ X ]¸ ¸eUG :#ÜÞ32, 63, 80ß

(45) ×} .j Ün¸Lc

(46) hÙÆCf ÜeJºÉ< ÜWVpp?fÑ Ük × ÙÆ ~0 ¥ ÙÆµ6ÙÆ0=+@;{X TK

(47) Ü ÙÆµ

(48) A5Ü ~0\

(49) ÙÆ[QÜ ÙÆÏÄ.u Ñ #=

(50) É £ × W¡n¸ Ün¸0{ ]RFwcW¡n¸Ñ¹n¸ W Vp§ÙÆm Â¨r

(51) ÜVJÙÆÏr

(52) )}Ü. 2.

(53) W:±Un¸GDn¸ Ü ÎÚ3060 M¤mÛ ª,n¸ ÜÊiÜ »ÕrÙÆµ &4>Üα2 Hc45OµÚα2 5OµÛC£¬a°µ «U. KÔ³ÙÆÚTIVAÛÏr

(54) Ü&4>PÓ. ¿?

(55) X P

(56) ÜÉ] 6Ö -

(57) Ü&4> TIVA ÑN¯ ÁÙ '+fO ØS _ 0=(."@;Ü5ÈË 5Î . Þ44, 66ßÜ4L¼¢fÑ Þ58ßTK

(58) ÜTIVA

(59) Î µ Ü× eJ

(60) &,:>@µ §¡ +· ·O¢ Þ8, 9, 47, 48, 61ß ÜÙÆ®y

(61) WVp?` Å Ü £ UUÒ Ü0=(."@;E eJ®yÎ>

(62) Þ52, 57ß ¶|Ü×

(63) ÙÆµ «U. . TK

(64) Ü8 &4>ÙÆÏr

(65)

(66) ÜyÙÆµ £ ´lh 0="!#$=> Ú2 ;.. =>Ú3α-hydroxy-5α-pregnane-11,. 20-dioneÛÜC£¬¨ >34-ÇÈ AÚGABAAÛHc4

(67) «UÜlº _§a°£¬0rUm#$=, ;.. =>Ü. 1971 k

(68) ; . , = > U 2 Ü ' + Althesin Ü O Saffan >=< T½ÑI

(69) Ü ¯2Ü(:! (;P

(70) '3!} Cremophor-EL

(71) »

(72) ÜA5 '# &4>ÈÕ5

(73) .9!@5h` Å TK

(74) Ü 1980 kR

(75) ½FCx Þ16, 20ß eÜ;.. => 2-. hydroxypropyl-β-cyclodextrin

(76) »y¯2Ñ

(77) ÜQ ;P. Ü NÙÆµ ¸8

(78) Þ49, 50, 55, 56ßÜ~ 2014 k 2 n

(79) ;.. >® ÜT½ÑI

(80) ;.. 3. >®Ü.

(81) «Å {rÜnr 4 Ü«²0rY Ü. [r

(82) ) . ]}Þ28ßµOtÜ¢¥ Ë

(83) Ã

(84) eÜPC£|

(85) g ~

(86) ÜÃry ÜºÉ#5@

(87) Þ22, 76ß ;.. =>ÜÞ44ßÞ76ß

(88) ÜÙÆ@uµG.

(89) Ü< eJªH §a°fÜpp?fÑ Ü

(90)

(91) ºÉf TK

(92) ÜfOØS ´lh Ç Ü×

(93) ÜeJµGDn¸ TIVA µ bØ 6TK

(94) Þ19, 29, 40, 42, 45, 59ßÜ jTÑ Ü´lh

(95) J 3M t²

(96) ×

(97) fO I CfÜÙÆ Ïr U

(98) _ [

(99) . Âx Ü. 9/<),¥Ä×

(100) ;.. => ´lµr.

(101)

(102) ÜA 3 bØ· ¦ 1 ¤ Ü. 9/<),

(103) ;.. => ÙÆeJµ . }r

(104) Ü7 × ´lh

(105) Ô³ÙÆ µÚ&4>(1>&@;Û;.. =>I)~0A Ã. eJºÉ

(106) ·O`´lr¾I

(107) ÜÙÆC WVp¨du ¬GP

(108) Ãt²

(109) ¦ 2 ¤ Ü. 9/<),

(110) ;.. => ´lµ`r.

(111) ÜÊi E@uBËÚ1.0 mg/kgÛ

(112) BÜ 2 !Ë Ú2.0 mg/kgÛ

(113) µOt`µN`r¾IG ÜuB Ë ÊeJ?ºÉ

(114) WVp¨

(115) SoÖ

(116) Ãt² e

(117) ¦ 3 ¤ Ü¦ 1 ¤¦ 2 ¤ «

(118) ÜVJÙÆµ;. . =>«U. ÅMÔ³ÙÆÚPIVAÛ

(119) t²ÙÆÎ 3. 4.

(120) Î*

(121) SLZa¸ 1 7

(122) Ü$2.;9>VJÙÆ

(123) ;.. =. >Ý6*+4">yÔ³LuBÚCRIÛG PIVA

(124) ÙÆ§·Ü ÙÆC´l}rt¶. 5.

(125) ¦1¤. 6*+4">Ý4'%95ÌÔA ;.. =>Ü&4>. (1>&@; eJ?ºÉ ´lr

(126) WVp¨

(127) SoÖ Ã. 6.

(128) 1. ¯ ¼ ;.. =>ÜÞ46ßÞ81ß

(129) ÜÙÆ@uµG.

(130) Ü< eJªH §a°fÜpp?fÑ Ü ºÉf ×

(131) Ü;.. =>. bØ 6 TK

(132) Þ19, 29, 40, 42, 45, 59ßÜGoodwin Ü $0=3">Ü!9">.!!>@uBe

(133) Ü;. . => eJ× Ü< eJªH ºÉ] ÎÙÆ . tfTK Þ27ß )© ÙÆeJµ Ü;.. => /

(134) Ü&4>Ü(1>&. @;0=(."@; »ÕrÙÆµ &4> Ü×Q

(135) ÙÆeJµÔ³ÙÆ )Å _ 6

(136) Î> ÙÆ@uB

(137) Ü&4>Ë < eJ

(138) Ü bN Ì5Üpp?fÑ

(139) Þ11, 54ßÜºÉ

(140) Ü»YÜ) ÌO_ÂÜ§¡ ` Å Þ54, 74ß ¿ Î5R; @;È¨ÙÆµ (1>&@;ÜÎ> ÙÆ@u B

(141) Ü&4>I

(142) Ë < eJÞ11, 75ß7 µ

(143) F

(144) PÜQ× ÙÆeJµ 6

(145) Ü9×e

(146) +w³Ü3z ÎyR WV Þ1, 11ßC£¬¨ GABAA Hc4

(147) 50 =(."@;ÜfOØS Ø

(148) 6

(149) Ü5ÈË Ü< ºÉf Þ44, 66ßÜ× eJ

(150) &,:> A5 Ü0=(."@;E e Jo TK

(151) Þ52, 57ß 9/<),

(152) M Ü µ;.. 7. =>I)~0A Ã.

(153) £ °Z Ü;.. =>/ ÙÆeJµ ´. lrÃÂrbØÀa

(154) Ü0=(."@;@Ã

(155) ÃM»ÒWÜ&4>(1>&@;Ïr × ´lU

(156) ÜÙÆeJ

(157) × KK. ÜÙ. Æ@uµ uB^Õ Þ54, 57ßα2 5Oµ 6*+4">Ü/ α2 5 Oµ

(158) ÌÔ5bN Üα2 Hc4 ÏrrÜÞ12, 13, 71, 79ß Ü>%"#>¹e4 4'%95G ÜªH Ì Ô§a°f Þ43ß ÜÙÆ@uµ 6 *+4">4'%95Ïr ¦ 1 ¤ Ü . 9/<),

(159) 6*+4">Ý4'%95ÌÔA ;.. =>Ü&4>(1>&@;

(160) eJ?ºÉ ´lr

(161). WVp¨du

(162) SoÖÃt²

(163) Ü. 9/<),

(164) . ÙÆeJµ }rt¶. 2. |} 1ÛH¿× 9/<), 6 ÖÚÐ 4 ÖÜÒ 2 ÖÛÜ5

(165) 16

(166) MÚÜbØ

(167) H¿ kÝ4Ð C^#ÚCÛÜ3.1 zÚ2.93.3 zÛÜ436 kgÚ370484 kgÛ. ×ÜbØ@ Æ4tr

(168) ´l

(169) %Wµl

(170) ÙÆ@ 12 ÎÚÜ§Û{ bØ5=#@ @

(171) ·Ü3 2 ÆÎ µÎÀÜI)× 3 @ bØ

(172) H¿ bØÜ~ C^¥×F¥Ä×®U £a ObØ,9>

(173) 1 bz

(174) Úb¸:Þ2014-M1Û . 8.

(175) 2ÛÙÆbØ0=+@; bØ&),kºÉLÚ6×6 mÛ ·µuB Ü RW×Ô³

(176) 14G-60 mm $@$;Ú#@&@# 14GÜ6*)+ÜpÛ ³µuB@

(177) Üqv{ÚHRÛ¡µ

(178) ÜWV{ÚRRÛ±¸

(179) aÜ D#6*+4">Ú6.0 μg/kgÞDorbene, Vetcare Oy, Salo, FinlandÛ4'%95Ú20 μg/kgÞ,;4 5Ü#$9#¯µÜp ÛI)!:>"

(180) Ô³LuB ÜH¿× 5 2 @ bØH ¿× 3 1 @ bØ Ü3M ÌÔtf

(181) 6*+4"> ÄBuB Ú2.0 μg/kgÛ^¾ ÙÆ@uB 10 Me

(182) .mÜHR RR a eÜ;.. =>Ú1.0 mg/kgÞAlfaxan, Jurox Pty Ltd, NSW,. AustraliaÛÜ&4>Ú2.5 mg/kgÞ&9@;Ü¦),¯µÜpÛ( 1>&@;Ú4.0 mg/kgÞ92@;ÜÂ¯µÜ]ÌÛ 10 * _ËÔ³LuBÙÆeJ ÓÜH¿×

(183) Ö=@0®Ü= @0E Üa

(184) À³

(185)

(186) Ê ÖÅ>+=@;Ü#>, . a×¤Û¦ JD

(187) #>,ÑjÜ. 9&v¦ JDbØC ×

(188) M ÜLLVJA §WV§ bz ÙÆeJµ uBª, 0 M

(189) ÀaHR RR ÜÌÔ@ÚD#ÛÜ ÌÔ 10 MeÜ0 M 5 M

(190) ÜHR RR ¡µ±¸

(191) aÙÆeJe AB ¹e qÓYÄ

(192) ³Ë+9>#*@ @Ú+9>#)+ BTK-TAS-0017Ü$>. @ "&>ÜpÛ. ¤Ûq Ü

(193)

(194) À³Ü#=sy·ÙÕO³ÜÙÕvO³ÜCÀO³

(195) 20G $@$;Ú. @.=@20G 2”Ü$;7ÜpÛ³ÜÙÆ±. !#$5ÚBSM-2300Ü~ +ÓÜpÛ Üp¨du ÜT±O. 9.

(196) ³[ÚSAPÛÜj\O³[ÚMAPÛwnO³[ÚDAPÛ 5 M

(197) ³Ë p¨du ³ËI&4> ÜO³¶h6Ü

(198) ¶#M ®³ÚABL800 FLEXÜ9"6@&@ÜpÛ

(199) O³¶È©M[ÚPaO2ÛÜ O³¶EÈP©M[ÚPaCO2Û pH aÙÆm¢]"Ú 5NÜe }ÛÄ

(200) 7%&:>/

(201) 4O¸ . ÜÔ³ $@$;Ò wO6WÜ§Å¦8· t . 3ÛeJºÉ ¾I ÙÆeJµuBª,v¦

(202) ÎÚeJÎÛaºÉ L l 3 m Ü

(203)

(204) À³_±ÊÜ»(m 69 ÜeJºÉ Ä

(205) 7%&@ÜDVD

(206) Ë9×ºÉ ¾ÜTable 1-1

(207) ¢ Mama 5 Î ¾IÞ48ß Ü5 ÙÆQË? Ñ(*

(208)

(209) ¾IÜ# C^#=9×ºÉ# ·Ü9×ßG5Úexcellentß< Ë 9×ÜªH §a°ÛÜG4 Úgoodß< v¦ ·ÜÖµ f

(210) O ÛÜG3Úfairßv¦

(211) Î¾Ü4 Ã §¯nµ O 1ÛÜG2ÚmarginalßÅ¦v¦ ·

(212) §O VBÛÜG1ÚpoorßÅ¦v¦ ·

(213) m Üµ &,:>Ü4Â§O VBÛºÉßG5ÚexcellentßÌO_ Â1.

(214) ÜfÑ ÌO_Â1Ü1 @ ¿ <

(215) Å¦ÛÜG4. Úgoodß¬V ÌO_Â1Ü1 @ ¿ Å¦ÛÜG3Úfairß2 @* ¿. Ü

(216) Å¦ÛÜG2Úmarginalß@Ô4Â O Å¦¿ÜÁm W:¼UUÛÜG1Úpoorß@Ô4Â O Å¦¿ÜÐm ºL ¼:

(217) ¨ÛÚTable 1-1Û Ü0 M / 4OÜ. 10.

(218) / ÖÅ c*Ü¤Û¦Ü/ Å¦ ¿Å¦

(219) ¾ÎÚÅ¦ ÎÛ³Ë. 4Û¬½» *@&C^#ÚCÛ ¹Ü3=

(220) .+ $; 3= 0:@!8>ÚExcel ¬½ ver.7.0ß #4ÜpÛ Ü->&96+:) »WVp¨ *@& Friedman ta MÜ}lS¸ UUÜµÎ Ã

(221) Steel-Dwass ÜI)µ D#;a# Ã

(222) Steel µÎ eJºÉ *@& Ã

(223) Ü Friedman ta MÜ}lS¸UUÜSteel-Dwass ¬½ }lS Pß0.05 . 3. « eJ# Table 1-2 Figure 1-1ÚAÛ

(224) ¢eJ#Ü;. . => G4ÚG35ÛÜ&4> G5ÚG45ÛÜ(1>&@; G4.5ÚG3. 5Û Ü3 µÎ

(225) }lS¸ &4>uB × ÜG4 * Ü¤Û¦v¦<

(226) ·)}Ü;. =>uB 6 ÖC 2 ÖÜ(1>&@;uB 6 ÖC 1 Ö

(227) ÜG3. Ü9× Ó

(228) Ám §¡?µ O ¸eJÎÜ &4>Ú67Ú5389ÛÛÜ;.. =>Ú49Ú4051ÛÛ(1. >&@;Ú48Ú4350ÛÛÍ;.. =>uB 6 ÖC 3. Ö

(229) Ü9×e

(230) +Ïlr O e¸Ü {M _. 11.

(231) p¨du ¬GP Table 1-3

(232) ¢;.. =>&4>. ÜÙÆ@uµ uBeÙÆC HR D#3#¢ÜK aÎ 3 µÎ

(233) }lS¸ ÜSAPÜMAP DAP KaÎ 3 µÎ

(234) }lS¸ WV¨du ¬GP Table 1-4

(235) ¢&4>uB 6 ÖC 4 Ö (1>&@;uB 6 ÖC 1 Ö &>$>ÚË WVÛW $xÚÍV

(236) W

(237) { ) W $xÛ ¸ )}Ü;.. =>uB 6 ÖC 5 ÖKaWV: 5®. y 3 µÜÙÆC RR D#

(238) Ã 3#¢ÜKa Î 3 µÎ

(239) }lS¸

(240)

(241) ÜPaO2ÜPaCOÞ pH KaÎ

(242) 3 µÎ

(243) }lS¸ ºÉ# Table 1-2 Figure 1-1ÚBÛ

(244) ¢ºÉ#Ü;. . => G4.5ÚG35ÛÜ&4> G3.5ÚG25ÛÜ(1>&@; G4. ÚG25Û Ü3 µÎ

(245) }lS¸ ;.. =>uB. × ÜG3 * Ü&4>uB 6 ÖC 2 Ö( 1>&@;uB 6 ÖC 1 Ö G2 ¾I

(246) ;ºÉa° Î Table 1-5

(247) ¢/ 4O ÎÜ3 µÎ

(248) }lS¸ ÜÅ¦Î

(249) Ü;.. =>Ú44Ú4063ÛMÛ(. 1>&@;Ú39Ú3058ÛMÛÜ&4>Ú25Ú1826ÛMÛÍ. 4. ² d ÙÆ@uµ

(250) Î> ÌÔ§a°f UUÜ&4> (1>&@;

(251) ÙÆeJÜ»YÜe`§¡` Å . 12.

(252) Þ11, 54ß×

(253) Üα2 5OµÜÙÆeJ@ ÌÔ§a° 6

(254) ¤ Üα2 5Oµ C ÌÔ5bN ÜÜ/ α2 5Oµ

(255) α2 Hc4 ÏrrÜÞ12, 13, 71, 79ß ÜÙÆ@uµ 6*+4">Ïr)}ÜGoodwin -'¿Ø

(256) Ü=4.">

(257) ÌÔe

(258) ;.. => ÙÆeJÓÜ»Y. m >+=@;BÖ t

(259) Í TK

(260) Þ27ß> %"#>¹e4 4'%95Ü Î ÌO_ÂJDOi Þ37ßÜ&4>

(261) eJ Ó

(262) i »Yp?Ü§a°V b Þ2ß

(263)

(264) Üα2 5Oµ>%"#>G

(265) Ü;E 6

(266) Ã ÜWVpp?` Å . ÜªH ÌÔtTK

(267) Þ43ß Ü bØ 3M ÌÔ§a°f [ÜÙÆ@uµ 6*+4">4'%95Ïr eJ#Ü3 µÎ

(268) }lS¸Ü9× ¾´l

(269) ć . &4>uB × Ü¤Û¦v¦<

(270) ·)}Ü;.. =>(1>&@;uB× {Ö Ü. eJ@

(271) 3M ÌÔtf

(272) Ï. Ü9× Ó

(273) Ám §¡. ?µ O ¸ÉG £Ü;.. =>(1>. &@; eJ

(274) ÜÙÆ@uµ

(275) .!!>G 9× ¾ J*8·r²Þ10, 23, 29ß eJÎ

(276) Ü&4>/ 2 µ

(277) Ã ÍÉG £. Ü=4.">

(278) ÌÔeÜ&4>"#&5uBÓ eJ Î 63.8 TK

(279) Þ41ßÜ&4>Ü0=(."@; (1>&@; Ã £

(280) ÜeJÎ&4>Í Ü(. 13.

(281) 1>&@; TK

(282) Þ23ß

(283)

(284) Ü/ £ Ü &4>;.. =>eJÎÍTK

(285) Þ42ß . «Ü bØ

(286) «Ú2 ;.. =>&4> ÜÙÆ@uµ uBeÙÆC

(287) HR. OÉG £ Ü;.. =>&4>

(288) HR

(289) S. oÖ

(290) }lS TK

(291) Þ40, 42ß)}Ü6*+4">Ú5 10 μg /kgÛ Ô³LuBe

(292) HR O TK

(293) Þ78ß Ü bØ ÙÆC

(294) HR OÜÙÆeJµ . 6*+4"> uB

(295) ÅA ² ×

(296) ÉG £ Ü&4>

(297) pp?Á\ TK

(298) Þ36, 54ßÜ;.. =>

(299) p¨w· oÖfÑ . TK

(300) Þ30ß)}Ü(1>&@;pp?` Å Þ67ßÜ^Å . TK

(301) Þ72ß bØ Ü3. µÎ O³¶[

(302) SoÖ

(303) }lS¸ bØ Üqv= Ëa Üp¨w· ¾I+3M Ü3 µÜÙÆ C p¨w·´l

(304) ć CL ®y

(305) ² RR ÜWV X Ê

(306) Ï. Ü3 µÎ

(307) }lS¸ Ù. ÆC PaCO2 × 50 mmHg @e®y ÜPaO2 ji × #Ú95 mmHgÛ

(308) Ã 3# Þ40ß Ü´lU

(309) Ü 3 µ6UU

(310) Ü¬Üf§

(311) È©VJ`C

(312) ºÉ#Ü;.. =>uB × G3 * Ü .

(313) ÌO_Â1¤m <

(314) Å¦(1>&@;&4>uB × Ü{Ö G2 ¾I

(315) Ü3 µÎ ºÉ#

(316) }lS¸. 14.

(317) iT

(318) ÜÙÆ@uµºÉ

(319) oÖS8·rds

(320) Þ34, 37ßÜ bØ

(321) Ü 8·r6a ÍÎ

(322). . ÙÆ®y

(323) UU

(324) ÜµÎ ºÉ ¾

(325) Ê ²

(326)

(327) ÜºÉ

(328) `CºÉ

(329) oÖS8·r² `CfÑ

(330) p

(331) bØ ¼T9>'5 Ü o Ö6a ÙÆeJµ uBª,/ 4O ÎÜ3 µÎ

(332) }lS¸ Ü&4> Ülº@g

(333) Å¦¿;J

(334) MÜ;.. =>(1>&@; Ü¤Û¦ t. ÎÍ;J

(335) Ü;.. =>(1>&@; Ü. &4>

(336) Å¦ÎÍÉG £ Ü!9">. !!>

(337) @uBe

(338) Ü(1>&@;&4> eJUUÜÅ¦ Î 3012 M 227 M TK

(339) Þ23ßÜ! 9">.!!>

(340) @uBe

(341) Ü;.. =>&4. > eJUUÜÅ¦Î 308 M 236 M TK

(342) Þ40ß

(343)

(344) Ü$0=3">Ü!9">Ü.!!>

(345) @u Be

(346) Ü;.. => eJUUÜÅ¦Î 4710 M TK

(347). Þ27ß TKÜ £*> _ ÃBÖ. Ü bØ «Ú2 bØ Àa&4>(1>&@; ËÜiT

(348) D za Ü ´lU ~i

(349) Ë Þ11, 24, 36, 54, 74, 75ß)}Ü;.. => ËÜY £zÀ

(350) -'bØ. «iTÞ27ß

(351) D zaÜ@6 3 µ Ë I NI}¶ BÖ bØ £Ñ Ü3 µ. 15.

(352) NIÜ. >0;{O ÜºÉ

(353) `C. oÖ

(354) Ü3 µ «

(355) ] S ² >0;{VUUÜµÎ

(356) S8·r6a . 5. f x ¦ 1 ¤ Ü;.. =>Ü&4>(1>&@;ÜeJ?ºÉ. ´lr

(357) WVpw·

(358) SoÖ

(359) I)~0A Ãt² «Ü;.. =>Ü&4>(1>&@; I. Ü;.. =>Ü. 9/<),

(360) Ü&4>. (1>&@;I

(361) ÜÙÆeJµ } ². 16.

(362) good. fair. marginal. poor. 4. 3. 2. 1. 17. exellent. good. fair. marginal. poor. 5. 4. 3. 2. 1. Recovery score. exellent. 5. Induction score. Mama et al. 1996 Mama et al. 1996. Multiple, uncoordinated attempts resulting in major or life-threatening injury (eg, broken limb). Uncoordinated attempts to stand with or without minor injury (eg, superficial laceration). Quiet recovery with more than 1 attempt to stand. Single attempt to stand with some ataxia. Single coordinated effort to stand with minimal to no ataxia. Vigorous struggling, paddling, limb movements increased coordinated muscular activity during the transition to lateral recumbency. Increased muscular activity prior to and during the transiton from standing to lateral recumbency. A slight delay in time to lateral recumbency with increased (compared with 4) muscular rigidity or limb movements. Smooth transition to lateral recumbency, minor facial or limb movements. Smooth timely collapse to lateral recumbency, good muscle relaxation. Table 1-1. Scoring scale for assessment of induction and recovery qualities. 6. Y ¹.

(363) 18 5 5. Ketamine Thiopental. 3. Thiopental 5. 5. Ketamine. Alfaxalone. 3. Alfaxalone. AKT. 1. 4. 3. 3. 5. 5. 4. ATK. 2. 4. 2. 4. 4. 4. 4. KAT. 3. 3. 2. 4. 5. 5. 3. KTA. 4. 5. 4. 5. 4. 5. 5. TAK. 5. 2. 4. 5. 5. 5. 5. TKA. 6. 4 (2-5). 3.5 (2-5). 4.5 (3-5). 4.5 (3-5). 5 (4-5). 4 (3-5). Median (Range). AKT means that the experiment was performed in order of alfaxalone, ketamine, thiopental.. The numbers in table represent scores as follows, 1: poor, 2: marginal, 3: fair, 4: good, 5: excellent.. Recovery score. Induction score. Order of the experiment. Horse No.. Table 1-2. Induction and recovery scores in 6 horses anesthetized with alfaxalone, ketamine or thiopental.

(364) 19 n/a n/a n/a. n/a n/a n/a. n/a n/a n/a. 36 (24-42) 36 (24-36) 31 (24-48). Statistical tests were not performed due to insufficient data.. * Significantly different from baseline values (P<0.05).. #. n/a: not applicable. n/a n/a n/a. n/a n/a n/a. n/a n/a n/a. 21 (18-24) * 22 (18-26) * 24 (20-29). (n=6). (n=6). Data are expressed as median (range).. Alfaxalone Ketamine Thiopental. DAP (mmHg). Alfaxalone Ketamine Thiopental. MAP (mmHg). Alfaxalone Ketamine Thiopental. SAP (mmHg). Alfaxalone Ketamine Thiopental. HR (beats/min). After premedication. Baseline. 93 (50-115) 86 (53-110) 95 (82-99). 113 (60-135) 103 (82-122) 106 (94-114). 139 (80-173) 145 (101-155) 129 (111-137). 26 (22-38) 26 (20-30) 26 (23-30). (n=6). 5 min. 89 (54-103) 86 (63-105) 88 (81-96). 102 (61-121) 102 (76-120) 106 (95-110). 121 (94-160) 143 (99-153) 127 (111-135). 24 (20-30) * 24 (22-27) * 24 (23-27). (n=6). 10 min. 93 (78-102) 80 (58-89) 82 (77-90). 109 (87-115) 98 (72-101) 98 (92-99). 134 (103-147) 125 (95-144) 124 (111-133). 23 (23-24) 25 (22-27) 25 (22-31). (n=x). 15 min #. (x=4) (x=6) (x=6). (x=4) (x=6) (x=6). (x=4) (x=6) (x=6). (x=4) (x=6) (x=6). Table 1-3. Heart rate (HR), systolic arterial blood pressure (SAP), mean arterial blood pressure (MAP) and diastolic arterial blood pressure (DAP) in 6 horses before premedication (baseline), after premedication and at 5, 10 and 15 minutes after administration of alfaxalone, ketamine or thiopental.

(365) 20. Alfaxalone Ketamine Thiopental. n/a n/a n/a. n/a n/a n/a. n/a n/a n/a. 14 (12-15) 14 (12-20) 15 (12-16). Statistical tests were not performed due to insufficient data.. * Significantly different from baseline values (P<0.05).. #. n/a: not applicable. n/a n/a n/a. n/a n/a n/a. n/a n/a n/a. 9 (7-10) * 9 (8-12) * 10 (8-12) *. (n=6). (n=6). Data are expressed as median (range).. pH. Alfaxalone Ketamine Thiopental. PaCO 2 (mmHg). Alfaxalone Ketamine Thiopental. PaO 2 (mmHg). Alfaxalone Ketamine Thiopental. RR (breaths/min). After premedication. Baseline. 7.385 (7.360-7.418) 7.384 (7.360-7.387) 7.406 (7.358-7.431). 49.1 (45.8-53.2) 51.9 (44.3-53.4) 49.8 (46.7-52.7). 67.4 (52.6-79.0) 66.6 (63.9-73.2) 77.2 (65.6-82.4). 7 (2-10) * 9 (4-20) 9 (5-13) *. (n=6). 5 min. 7.397 (7.369-7.413) 7.368 (7.353-7.391) 7.406 (7.364-7.419). 47.6 (46.1-51.2) 49.9 (46.3-55.6) 50.6 (45.8-54.7). 80.5 (66.2-85.4) 68.7 (66.2-72.7) 77.9 (69.2-83.3). 8 (3-16) 6 (4-10) * 10 (5-12) *. (n=6). 10 min. 7.384 (7.372-7.425) 7.383 (7.334-7.388) 7.411 (7.367-7.425). 50.7 (46.9-52.5) 51.0 (46.3-54.7) 49.4 (46.9-52.5). 77.7 (49.4-89.0) 72.7 (66.1-81.8) 78.1 (75.3-83.6). 8 (5-10) 8 (5-17) 9 (7-12). (n=x). 15 min #. (x=4) (x=6) (x=6). (x=4) (x=6) (x=6). (x=4) (x=6) (x=6). (x=4) (x=6) (x=6). Table 1-4. Respiratory rate (RR), arterial partial pressure of oxygen (PaO 2), arterial partial pressure of carbon dioxide (PaCO 2) and blood pH in 6 horses before premedication (baseline), after premedication and at 5, 10 and 15 minutes after administration of alfaxalone, ketamine or thiopental.

(366) 21. 18 (15-26). 19 (15-23). Ketamine. Thiopental. a,b,c,d. 24 (20-26). 21 (16-26). 30 (12-42) 27 (23-37). 21 (16-26). 32 (19-42). (min). Sternal recumbency. (min) 44 (40-63) c 25 (18-26) d 39 (30-58) c. 44 (23-63) ab 25 (17-26) a 34 (30-58) b. Standing. (min). First attempt to stand. Values in a column with different superscripts are significantly different (P<0.05).. Data are expressed as median (range).. 17 (11-28). (min). (min). Alfaxalone. First head lift. First movement. Table 1-5. Time from the end of anesthetic induction drug (alfaxalone, ketamine or thiopental) administration to first movement, first head lift, sternal recumbency, first attempt to stand and standing.

(367) 22. . .

(368) .

(369) . . . . . . . # !. . .

(370) . . . ". .

(371) " # ! . . . " !. . . . . . . . !. !. . .

(372) ¦2¤. 6*+4">Ý4'%95ÌÔA 2 Ë

(373) ;.. => µOt`µN`r ¾I. 23.

(374) 1. ¯ ¼

(375) ;.. => µOtµN`

(376) Ï £ÜE). Ë ½{ Ë

(377) TK

(378) Þ22, 76ß´l `C Ë

(379) t1/2 ÜÚ2.0 mg/kgÛ Ü24.0 MÞ22ßÜÚ5.0 mg/kgÛ Ü 45.2 MÞ76ß TK

(380)

(381) Ü;.. =>. Ë

(382) Ã_ÜCRI

(383) Îµ`r}TK

(384) Þ5, 22, 65ß ×

(385) ;.. => uB

(386) Ï £ TK

(387) . Þ19, 29, 40, 42, 45ßÜm×

(388) ;.. => µOtµN`

(389). ÏTKÜ2 T

(390) Þ27, 30ßGoodwin Ü#&>'@,/< ),

(391) Ü$0=3">Ü!9">.!!> @uBe

(392) Ü;.. =>Ú1.0 mg/kgÛE@uB Ü/ O¥I

(393) Ü. Ë

(394) ¶C_

(395) Ü< eJKK ºÉfTK Þ27ßÜ#&>'@,/<),

(396) Ü$0=3">Ü!9" >.!!> @uBe

(397) Ü;. JÜ;.. =>Ú1.0 mg/kgÛ

(398) e. => CRIÚª 3.0 mg/kg/hrÛ ®y· Ü µ. OtÜE@uBÚ2« TK Þ30ß µ MhÜÃg~ µOtÜkÝÜ=¥ÜÆ4tG µ Ü

(399) ¾A

(400) oÖH Ü bØÀa iT µOtµN` «Üd. 9/<),¥Ä. ×

(401) Î o ÜGoodwin TK Ü1 Ë uB

(402) ÜuBË Ê

(403) oÖÜ

(404) ÜË A5

(405) Ü3M

(406) t¶

(407) Ü¦ 2 ¤ Ü6*+4">Ý4'%95 ÌÔA. 9/<),

(408) ÜÊi uBËÚ1.0 mg/kgÛ

(409) BÜ 2 !Ë. 24.

(410) Ú2.0 mg/kgÛ ;.. =>E@uBÜµOt»

(411) Üe. J?ºÉ ´lr

(412) WVp¨

(413) SoÖÃt². 2. |} 1ÛH¿× . 9/<), 7 ÖÚÐ 6 ÖÜÒ 1 ÖÛ5

(414) 17

(415) MÚÜbØ

(416) H¿. kÝ4Ð C^#ÚCÛÜ3.1 zÚ2.03.4 zÛÜ466 kgÚ427484 kgÛ. ×ÜbØ@ ´ltr

(417) %Wµl

(418) ÙÆ@ 12 ÎÚÜ§Û{ bØ5=#@@

(419) ·Ü3 2 ÆÎ µÎÀÜI)× 2 @ bØ

(420) H¿ bØ Ü~ C^¥×F¥Ä×®U £a ObØ,9>

(421) 1 bz

(422) Úb¸:Þ2014-M2Û. 2ÛÙÆbØ0=+@; bØ&),kºÉLÚ6×6 mÛ ·µuB Ü RW×Ô³

(423) 14G-60 mm $@$;Ú#@&@# 14GÜ6*)+ÜpÛ ³ÜÔ³¶h6 Ü9W×Ô³

(424) I

(425) $@$;³ µuB @

(426) ÜHR ¡µ

(427) ÜRR ±¸

(428) aÜ D# 6*+4">Ú6.0 μg/kgÞDorbene, Vetcare Oy, Salo, FinlandÛ4 '%95Ú20 μg/kgÞ,;4 5Ü#$9#¯µÜpÛI)!:>"

(429) Ô ³LuBÙÆ@uB 10 Me

(430) .mÜHR RR a eÜ ;.. =>ÚAlfaxan, Jurox Pty Ltd, NSW, AustraliaÛ1.0 mg/kg . 2.0 mg/kg Ë 10 * _ËÔ³LuBÙÆeJ ÓÜH¿×

(431). 25.

(432) Ö=@0®Ü=@0E Üa

(433) À³

(434)

(435) Ê ÖÅ> +=@;Ü#>,. a×¤Û¦ JD

(436) . #>,ÑjÜ9&v¦ JDbØC ×

(437) M ÜLL VJA §WV§bz ÙÆeJe AB ¹e qÓYÄ

(438) ³Ë+9>#*@ +9>#)+ BTK-TAS-0017Ü$>. @Ú. @ "&>ÜpÛ¤Ûq. Ü

(439)

(440) À³Ü#=sy·ÙÕO³ÜÙÕvO³

(441) 20G $ @$;Ú. @.=@20G 2”Ü$;7ÜpÛ³ÜO³¶[ a. >. 0;h6· ;.. => uBª, 0 M

(442) ÀaÙÆ±!#$5ÚBSM-. 2300Ü~ +ÓÜpÛ ÜHRÜSAPÜMAP DAP Ü4O¸ 5 M

(443) ³ËWV{Ü±¸

(444) 5 M

(445) ap¨d u ³ËI&4> ÜO³¶h6Ü

(446) ¶#M®³ ÚABL800 FLEXÜ9"6@&@ÜpÛ

(447) PaO2ÜPaCO2 pH a /

(448) 4O¸ ÜÔ³ $@$;Ò wO6 WÜ§Å¦8· t. 3ÛeJºÉ ¾I ;.. => uBª,v¦

(449) ÎÚeJÎÛa. Ü»(m 69 ÜeJºÉÄ

(450) 7%&@ÜDVD

(451) Ë 9×ºÉ ¾ÜTable 1-1

(452) ¢ Mama 5 Î ¾IÞ48ß Ü5 ÙÆQË?Ñ(*

(453)

(454) ¾IÜ# C^#=0 M / 4OÜ/ ÖÅ c*Ü¤Û¦Ü/ Å¦ ¿Å¦

(455) ¾ÎÚÅ¦ÎÛ³Ë. 26.

(456) 4Û¶C;. ;.. =>M. =>uBÑI 2, 4, 6, 10, 15, 20, 60, 120, 240 MeÅ¦e

(457). &:>+:5Bh¶§Ú-"!+h¶§ VP-H100KÜ$; 7ÜpÛ

(458) Ô³¶ 10 ml h6 >0;

(459) x)ÜMÕ¶ Ý20. [. ¶ @+\=

(460) DnÜ¶C;.. =>m. Ü4=3+9.@Á&>*5¾ËMÚLC-MS/MSÛ aË 1 μg/ml 11-',=!0=#$=>7

(461) 6&-@; 10 μl Lu ¾ ¿Ø§

(462) BÜ¶ 0.5 ml BÜ

(463)

(464) 6(; tert-/(; @$; 3 ml BÜ5 MÎ3M

(465) X}wM¿Ø§

(466) MÜ©~A Z w 10 mmol/l È>7%5?$+%+:;Ú1:1, v/vÛ200 μl

(467) .»Ü 20 μl LC-MS/MS M

(468) H;.. =>. M

(469) Ïr5h7%&:>Ü <+=#0<@>P y>7 @,

(470) a4=3+9.@Á&>*5¾ËM

(471) Ü Prominence HPLC !#$5ÚO}¯5aÜpÛ QTRAP 4000ÚSciex, MA, USAÛ«U. Ïr5h7%&:> ~0Ü;.. =>.

(472) m/z 333 215ÜLu¾ 11-',=!0=#$=>

(473) . m/z 331 295 aË¿Ø

(474) tË°Ü0.0110 μg/ml C u °c@^

(475) =ÜM «Ü Ï#{ 0.995 *ÚÐ# { 1/y2Û¢ aË

(476) ×¶ ;. @TÜ0.2 μg/ml ;.. =>B@T¿Ø

(477). => 20 ng/ml 11-',=!0. =#$=>B¶6Ü11-',=!0=#$=> ;. => @Tÿ« 99.3%Ú3.0%Û Ü0.1 μg/ml ;.. =>B¶6B@T¿Ø

(478) ÜmÚn=5Û 97.6%. 27.

(479) 107.3%Ü©mÚn=5Û 4.8%¢. 5Û;.. => µOt». ; & 4 ; Ë m M Î * @ & µ O t »

(480) Ü Phoenix WinNonlin 7.0ÚCertara USA Inc., NJ, USAÛ Ü->>&@+6>+» ·_ÚλÛ Ëma{mMÎ M{9. °c@^

(481) à_RÚt1/2 ÛÜλ =¶CmÎ°AÕ¢ ÚAUCÛ 1 7@6>+°AÕ¢ÚAUMCÛÜ0 ªaËÎ. ÚAUC0-tlast AUMC0-tlastÛ4c(X

(482) =Ü0 ÑÎ. ÚAUC0-inf AUMC0-infÛ AUC0-tlast AUMC0-tlast ®X

(483) Wf° B ¹j\ÎÚMRTÛ

(484) ÜAUMC0-inf AUC0-inf Ò =Ü®:9>#ÚClÛ

(485) ÜuBË AUC0-inf Ò =

(486)

(487) ÜaitMhc¢ÚVdssÛ

(488) ÜCl

(489) MRT = . 6Û¬½» *@&C^#ÚCÛ ¹Ü3=

(490) .+ $; 3= 0:@!8>ÚExcel ¬½ ver.7.0ß #4ÜpÛ Ü->&96+:) »WVp¨du *@& Friedman ta MÜ}lS¸ UUÜËÎ Ã

(491) Wilcoxon :¼taÜI)Ë D#; a# Ã

(492) Steel ËÎ eJºÉ *@& Ã

(493) ÜWilcoxon :¼ta¬½}lS P < 0.05 . 28.

(494) 3. « eJ# Table 2-1 Figure2-1ÚAÛ

(495) ¢eJ#eJ ÎÜ1.0 mg/kg G4ÚG35Û 50Ú3660ÛÜ2.0 mg/kg G5 ÚG45Û 35Ú2260Û Ü

(496) ËÎ }lS¸ 1.0 mg/kg uB× 7 ÖC 2 Ö Ü¤Û¦v¦

(497) ·Ó

(498). §e`?µ Oi¸Ü2 ËÜ9×e

(499) +Ïl. r O e¸Ü {M _ p¨du ¬GP Table 2-2

(500) ¢HR 2 ËD#Ã ÜÌÔeÙÆC

(501) OÜKaÎ

(502) ËÎ }lS¸ ÜSAPÜMAP DAP ËÎ¬ }lS ¸ WV¨du ¬GP Table 2-3

(503) ¢RR 2 Ë D#Ã ÜÌÔeÙÆC

(504) O

(505)

(506) Ü2.0 mg/kg uB ª, 5 Me 10 Me

(507) 1.0 mg/kg 3#¢PaO2 pH Ü2.0 mg/kg uBª, 10 Me

(508) 1.0 mg/kg 3#¢PaCO2 Ü2.0 mg/kg. uBª, 5 Me 10 Me

(509) 1.0 mg/kg Ü#¢ ºÉ# Table 2-1 Figure 2-1ÚBÛ

(510) ¢ºÉ#Ü1.0 mg/kg G5ÚG35ÛÜ2.0 mg/kg G5ÚG35Û ÜËÎ }lS ¸ 2.0 mg/kg uB× 7 ÖC 2 Ö Ü)Ér

(511) Å¦e » Ée;ºÉa° Î Table 2-4

(512) ¢4OÜ/ Å ¦ ¿Å¦ÎÜ2.0 mg/kg 1.0 mg/kg Í ×

(513) ÜÅ¦e UG¸ ¶C;.. =>m ¬GP Figure 2-2

(514) ¢Ô³LuBe. Ë

(515) _ÜuBª, 20 Me°

(516) _Å¦e ¶C;. . =>mÜ1.0 mg/kg 0.50Ú0.410.64Ûμg/mlÜ2.0 mg/kg 0.82. 29.

(517) Ú0.501.10Ûμg/ml ;. => µOt&96@&@ Table 2-5

(518) ¢t1/2ÜCl Vdss Ü1.0 mg/kg Ü58.2Ú42.370.7ÛMÜ 11.6Ú10.314.5Ûml/min/kg 0.8Ú0.70.9Ûl/kg Ü2.0 mg/kg Ü 59.8Ú47.568.0ÛMÜ14.7Ú12.116.0Ûml/min/kg 0.9Ú0.91.2Ûl/kg. . 4. ² d 2 ËÎ 9× ¾

(519) }lS¸ Ü1.0 mg/kg Ü¤Û¦ v¦

(520) ·Ó

(521). §e`?µ Oi¸;.. =>

(522) ÙÆeJUUÜ.!!>ÙÆ@uB9× ¾ J* TK

(523) Þ27ß Ü´lU ;.. =>6. ÓÜ.!!> ÙÆ@uB`C

(524) Ü bØ ÜµO tµN` oÖfÑ

(525) pÜ.!!> ÙÆ@uB ·. )}Üα2 5Oµ>%"#> GÜ;E U. U

(526) Ã ÜWVpp?` Å ÜªH ÌÔt Þ43ßÜ bØ ÙÆ@uµ

(527) 6*+4">4'%95G eJÎÜ2.0 mg/kg 1.0 mg/kg

(528) Ã Ü2 ËÎ } lS¸ Goodwin ÜÐ ×

(529) $0=3">Ü6* +4">.!!>

(530) ÌÔeÜ;.. =>Ú1.0 mg/kgÛ. eJ Üj\eJÎ 36 TK Þ29ßÜ#& >'@,/<), m×

(531) $0=3">Ü!9">.! !>

(532) ÌÔeÜ;.. =>Ú1.0 mg/kgÛ eJ Üj\eJ. Î 53 TK Þ30ß «Ü bØ «Ú2. 30.

(533) Ü¬Ý. 9/<),

(534) ÜÎ> ÌÔtf. UUÜÙÆeJ

(535) ;.. => Ë 1.0 mg/kg ÎZ . ² Grimsrud Ü×

(536) 6*+4">Ú510 μg/kgÛ uBe

(537) ÜHR OTK Þ34ß Ü bØ ÙÆC HR OÜ ;.. =>§4

(538) Ü

(539) 6*+4"> uB

(540) ÅA . ²

(541)

(542) ÜÙÆC MAP ÜÜË 2.0 mg/kg ÜÙÆA ×

(543) ćCL {# ` bØ Üqv=Ëa Üp¨w· ¾I+3M Ü bØ uBË CL Üp p?Á\ ²

(544) Ü;.. =>

(545) WVp?TK

(546) Þ5, 76ß. Goodwin Üy×

(547) ;.. =>Ú3.0 mg/kgÛ

(548) eJe

(549). RR OÜ5 ÖC 3 Ö eJe

(550) 3È©¶¸TK Þ28ß bØ

(551) ÜÜË 2.0 mg/kg ÜWV¸ÜPaCO2 ÙÆA ×

(552) ćCL {# `)}ÜÙÆC PaO2 Ü3 Ë 1.0 mg/kg Üji × #Ú95 mmHgÛ

(553) Ã 3#¢ Þ40ß×

(554) Ü3È©¶Ü3zÜz¶~ +\§ÜL!>+ wg¹G

(555) ` Å

(556) bØ

(557) 3È© ¶ 3A

(558)

(559) Ü· Âr^¾ ÜÐ 3È©¶1WVp?Ü;. Ü´lU ;.. => o }G.» . =>6UUÜ3È©¶¸x.

(560) È©VJ^Õ ² ºÉ ÎË8[r

(561) UÍ×

(562) Ü3È©¶Ü3¶[ÜÈ ?DMhÜÍ¹G{¡ÜºÉ ÎUÍ . 31.

(563) Þ17ß bØ

(564) Ü2.0 mg/kg ºÉ ²UÜ3È©¶ ¾A 1 ²ºÉ ¾Ü × ´l

(565) ćCL #. Ü2.0 mg/kg Ü)Ér

(566) Å¦e » ÉeiT